Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (41-50 of 135) with videos related to

Pageof 14
Sort By:
Internal Medicine Journal|May 20, 2024
Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologistsAlexandra Flynn, Peter Galettis, Howard Gurney, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 18, 2019
Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patientsAtul Bhatnagar, Matthew J McKay, Morten Thaysen-Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide TreatmentGerhardt Attard, Michael Borre, Howard Gurney, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2017
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringDhanusha Sabanathan, Alison Zhang, Peter Fox, et al.
Frontiers in Immunology|March 23, 2026
Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcomaBrie-Anne Mannah, Fei Yang, Lijia Yu, et al.
Cancer Medicine|November 21, 2022
Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centresLauren J Brown, Ines Pires da Silva, Tania Moujaber, et al.
The AAPS Journal|August 7, 2013
Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2Fanfan Zhou, Jian Zheng, Ling Zhu, et al.
Endocrine Connections|March 24, 2022
Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patientsVita Birzniece, Teresa Lam, Mark McLean, et al.
BMJ Open|June 29, 2018
Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviewsMarina T van Leeuwen, Steven Luu, Howard Gurney, et al.
Pharmacology Research & Perspectives|July 15, 2020
Nuances to precision dosing strategies of targeted cancer medicinesAshley M Hopkins, Bradley D Menz, Michael D Wiese, et al.
Pageof 14

Showing results (41-50 of 135) with videos related to

Sort By:
Pageof 14
Internal Medicine Journal|May 20, 2024
Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologistsAlexandra Flynn, Peter Galettis, Howard Gurney, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 18, 2019
Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patientsAtul Bhatnagar, Matthew J McKay, Morten Thaysen-Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide TreatmentGerhardt Attard, Michael Borre, Howard Gurney, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2017
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringDhanusha Sabanathan, Alison Zhang, Peter Fox, et al.
Frontiers in Immunology|March 23, 2026
Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcomaBrie-Anne Mannah, Fei Yang, Lijia Yu, et al.
Cancer Medicine|November 21, 2022
Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centresLauren J Brown, Ines Pires da Silva, Tania Moujaber, et al.
The AAPS Journal|August 7, 2013
Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2Fanfan Zhou, Jian Zheng, Ling Zhu, et al.
Endocrine Connections|March 24, 2022
Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patientsVita Birzniece, Teresa Lam, Mark McLean, et al.
BMJ Open|June 29, 2018
Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviewsMarina T van Leeuwen, Steven Luu, Howard Gurney, et al.
Pharmacology Research & Perspectives|July 15, 2020
Nuances to precision dosing strategies of targeted cancer medicinesAshley M Hopkins, Bradley D Menz, Michael D Wiese, et al.
Pageof 14